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What is already known on this topic?
 ► Problems with outcome selection and reporting 
are an important cause of research waste in 
many fields.
 ► Neonatal conditions and treatments affect 
outcomes that extend throughout childhood 
into adult life.
 ► Neonatal systematic reviews are increasingly 
unable to identify optimal treatment options 
due to problems combining evidence from 
heterogeneous trials.
What this study adds?
 ► Neonatal trials report a range of outcomes, 
using disparate outcome measures, at many 
different time points.
 ► We found no evidence of involvement of 
patients and parents in outcome selection for 
neonatal trials.
 ► Developing a neonatal core outcome set will 
ensure research translates into improvement in 
neonatal care.
AbsTrACT
Objective Inconsistent outcome selection and reporting 
in clinical trials are important sources of research waste; 
it is not known how common this problem is in neonatal 
trials. Our objective was to determine whether large 
clinical trials involving infants receiving neonatal care 
report a consistent set of outcomes, how composite 
outcomes are used and whether parents or former 
patients were involved in outcome selection.
Design A literature search of CENTRAL, CINAHL, 
EMBASE and MEDLINE was conducted; randomised trials 
published between 1 July 2012 and 1 July 2017 and 
involving at least 100 infants in each arm were included. 
Outcomes and outcome measures were extracted and 
categorised by physiological system; reported former 
patient and parent involvement in outcome selection was 
extracted.
results Seventy- six trials involving 43 126 infants were 
identified; 216 different outcomes with 889 different 
outcome measures were reported. Outcome reporting 
covered all physiological systems but was variable 
between individual trials: only 67/76 (88%) of trials 
reported survival and 639 outcome measures were only 
reported in a single trial. Thirty- three composite outcomes 
were used in 41 trials. No trials reported former patient 
or parent involvement in outcome selection.
Conclusions Inconsistent outcome reporting and a lack 
of parent and former patient involvement in outcome 
selection in neonatal clinical trials limits the ability of 
such trials to answer clinically meaningful questions. 
Developing and implementing a core outcome set for 
future neonatal trials, with input from all stakeholders, 
should address these issues.
InTrODuCTIOn
Neonatal conditions are a leading cause of morbidity 
and mortality in childhood. Globally 2.7 million 
babies1 die annually in the neonatal period, and in 
high- income countries approximately 1 in 10 babies 
will be admitted to a neonatal unit.2 Furthermore, 
neonatal conditions have long- term effects on 
all physiological systems3 that extend into adult-
hood.4 Caring for these babies also has a substantial 
financial cost: the additional costs incurred during 
childhood for babies born prematurely in the 
United Kingdom has been estimated at £3 billion 
each year.5 
Neonatal patients are extremely vulner-
able: they often need multiorgan support6 and 
treatments given for one condition can have 
unexpected adverse consequences in other physio-
logical systems.7–10 To receive optimal care a robust 
evidence base is required, so clinicians can make 
the complex decisions around benefits and risks of 
different treatments. Unfortunately there is a lack of 
evidence for many neonatal practices, which leads 
to variation in both care provision11–13 and neonatal 
outcomes.13–15 A review of Cochrane reviews in 
neonatology found that over 50% of recent reviews 
were inconclusive; key factors hindering effective 
evidence synthesis are heterogeneity of trials and 
poor methodological quality of studies.16
Poor outcome selection, collection and reporting 
are increasingly recognised as barriers that limit 
the applicability of research to clinical practice.17 18 
Poorly selected outcomes may make trial findings 
meaningless to patients or clinicians19; poor outcome 
reporting can cause publication20 and reporting 
bias21; and disparate outcome selection can make 
subsequent meta- analysis impossible.22 These prob-
lems exist in many other fields23 24; several system-
atic reviews have shown that heterogeneity of 
outcome reporting is a particular problem in trials 
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composite outcomes in clinical trials can further contribute to 
research waste29: individual components within a composite may 
not be equivalent30 and such endpoints may be difficult to inter-
pret in trials where the intervention has opposite directions of 
effect on different outcomes within a composite.31 Some paedi-
atric fields have also found that outcomes are selected to address 
the needs of researchers32 rather than patients and parents.33 
Public and patient involvement leads to research that is more 
relevant and useful,34 but evidence from other fields indicates 
that involvement in trial outcome selection is limited,35 although 
this has not been assessed in neonatal trials.
The aims of this review were to determine the range and 
heterogeneity of outcomes reported in randomised controlled 
trials of interventions involving infants receiving neonatal care, 
and whether former patients or parents were involved in the 
selection of outcomes.
MeThODs
We prospectively registered the study on PROSPERO (Prospec-
tive Register of Systematic Reviews): CRD4201604211036 
and conducted it in line with Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses (PRISMA) guidelines37 
using methods based on previous systematic reviews exploring 
outcome reporting across randomised trials.25–27 We identified 
studies by searching: Cochrane Central Register of Controlled 
Trials (CENTRAL); Cumulative Index to Nursing and Allied 
Health Literature (CINAHL); Excerpta Medica database 
(EMBASE) and Medical Literature Analysis and Retrieval System 
Online (MEDLINE). We searched databases from 1997 to July 
2017, but due to the large number of studies included the search 
period was limited from 1 July 2012 to 1 July 2017.
We included studies if they were randomised controlled trials 
or cluster- randomised trials involving neonates or any infants 
requiring ongoing care in a neonatal unit beyond the neonatal 
period; care provided exclusively on postnatal wards or in an 
outpatient environment was excluded. We last searched the data-
bases on 19 July 2017, and only considered studies in English. 
The search strategy for CINAHL is included as online supple-
mentary eFigure 1. Three authors (SA, SS, JW) independently 
double screened potentially relevant records based on titles and 
abstracts, and reviewed the full text of selected studies to assess 
eligibility. Due to the high number of trials identified, we only 
analysed large neonatal trials (defined as over 100 infants in each 
arm of a study). As many trials lead to more than one publication, 
we sought out all publications using trial registration records to 
ensure we had a comprehensive record of the outcomes reported 
for each trial. To avoid duplication of results if multiple publi-
cations related to a single trial met our inclusion criteria, we 
only included the first paper (with all outcomes coded as above). 
Three authors (SA, SS and JW) then extracted and categorised 
outcomes and outcome measures. An ‘outcome’ was defined as 
the beneficial or harmful effect a treatment has on an individual 
while ‘outcome measure’ was defined as the metric used to char-
acterise this response, in line with Core Outcome Measures in 
Effectiveness Trials (COMET) initiative guidance.38 In the case 
of discrepancies between the authors during screening or coding, 
the study was reassessed by three researchers (SA, SS and JW) 
with input from an additional reviewer (CG) and a majority 
opinion sought. All screening and coding was undertaken using 
Eppi- Reviewer 4 software.39
We extracted data using a pilot- tested and standardised data 
extraction form including study characteristics such as trial iden-
tifiers, participants and evidence of a protocol/pre- registration. 
We systematically extracted all outcomes (eg, bronchopulmo-
nary dysplasia), outcome measures and measurement time points 
(eg, receiving respiratory support or supplemental oxygen at 
28 days) reported in individual clinical trials. We extracted all 
outcomes reported in the results section or in results tables. If 
it was clearly stated that outcomes would be measured in the 
future we also recorded this (particularly if participants are still 
too young for long- term outcomes to have been reported). We 
categorised outcomes using a predefined framework of physio-
logical systems40: major systems were respiratory, cardiovascular, 
gastrointestinal, genitourinary, neurological, infection, pain and 
neurodevelopmental outcomes; this was developed iteratively as 
the study progressed. This was used because frameworks from 
other fields did not relate well to neonatal care41 42 or missed 
key concepts.38 We also examined the frequency with which 
predefined neonatal comorbidities are reported in the largest 
trials.43
We extracted data relating to how frequently parents or 
patients were involved in the choice of outcomes in identified 
trails from trial publications and protocols where these were 
available.
We assessed the methodological quality of the included studies 
using the Jadad criteria.44
resulTs
Searches identified 24 214 records for screening. A total of 76 
randomised trials reporting data from 43 126 infants met the 
inclusion criteria (figure 1, online supplementary eTable 1). Fifty 
six trials (74%) involved infants born extremely preterm (gesta-
tional age at birth <28 weeks), 54 trials (71%) involved infants 
born very preterm (gestational age at birth between 28 and 32 
weeks) and 25 trials (33%) involved moderate and late preterm 
infants (gestational age at birth between 32 and 37 weeks). By 
contrast only eight trials (11%) involved term infants. Study 
quality was good; 72 trials (95%) scored three or above on the 
Jadad scale (online supplementary eTable 1).
Across 76 trials 216 distinct outcomes were reported (online 
supplementary eTable 2). The most commonly reported 
outcome was survival; reported in 67 trials (88%). The next 
most commonly reported outcomes were necrotising entero-
colitis (53 trials (70%)); bronchopulmonary dysplasia (50 trials 
(66%)); sepsis (48 trials (63%)) and retinopathy of prematurity 
(43 trials (57%)). In relation to neurodevelopmental outcomes, 
visual impairment or blindness were only reported in 21 trials 
(28%) and 42 trials (55%) did not report any developmental 
outcomes (online supplementary eTable 3). Even among the 10 
trials involving the largest numbers of infants, major neonatal 
conditions were not universally reported (figure 2). Of the 
216 outcomes reported, 92 were only reported in a single trial 
(figure 3).
Where trials reported the same outcomes, for example, 
retinopathy of prematurity, these may not be comparable if 
different outcome measures are used; for example, bilateral 
retinopathy of prematurity stage ≥3 and retinopathy of prema-
turity needing surgery (figure 3). Sepsis was recorded using 43 
different outcome measures (online supplementary eTable 4); 
bronchopulmonary dysplasia 16 outcome measures and necro-
tising enterocolitis 13 outcome measures. In relation to the 216 
outcomes, 889 different outcomes measures were reported; of 
these, 639 were only reported in a single trial.
We identified that neonatal trials reported multiple outcome 
measures, using a number of different time points. The earliest 
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Figure 1 PRISMA flow chart of included papers. NICU, neonatal intensive care unit; PRISMA, Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses. 
Figure 2 ORBIT (Outcome Reporting Bias In Trials) figure illustrating 
outcome reporting in 10 largest trials. Legend: •Outcome reported in 
this paper. *Outcome reported in previously published paper relating to 
this research sample. ○ Outcome documented as planned to be reported 
in the future.
latest reported outcomes were reported at 20 years of age.46 
When considering individual outcomes, survival was reported 
at 23 different time points (figure 4): of these, 16 related to 
chronological age (ranging from 72 hours of age to 20 years); 
3 related to postmenstrual age; 3 to study time points and 1 
to discharge from hospital: the most consistently reported was 
survival to discharge home, reported in 37/76 trials (49%). We 
considered the combined impact of outcome measures and time 
points by looking for a comparable outcome measurement and 
time point reported consistently across trials (table 1).
Composite outcomes were used in 41 trials (54%); the most 
commonly reported composite being a composite of death and 
bronchopulmonary dysplasia (13 trials (17%)). This composite 
was reported using six different measures and at two time 
points. There was heterogeneity among composites: 33 different 
composite outcomes were reported (online supplementary 
eTable 5) using 69 incomparable composite outcome measures, 
with 58 of these outcome measures only reported in a single 
study.
Among 76 included trials and after reviewing published papers 
and protocols where available, we found that no trial reported 
patient or parent involvement in outcome selection.
DIsCussIOn
This review quantifies the range and inconsistency of outcome 
selection, measurement and reporting in large neonatal trials; this 
identifies outcome reporting as a major source of research waste 
in neonatology. There are multiple factors that contribute to this 
problem: heterogeneous and incomparable outcome measures 
are used, outcomes are reported at multiple time points (which 
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Figure 3 Hierarchical representation of outcomes recorded in 76 large neonatal trials. Legend: Outcomes ordered by domain. Number in italics 
illustrates number of studies reporting outcome. Outcome names truncated. All outcomes listed in full in same order in online supplementary eTable 
2. Outcomes in red reported in only a single study. Outcome measures for retinopathy of prematurity (ROP) and intracranial haemorrhage (ICH) 
displayed to illustrate further heterogeneity of outcome measures.
Figure 4 Discrete time points at which survival was measured. 
Legend: Italicised number in brackets is the percentage of studies that 
reported survival at each time point.
is widespread. Finally, we were unable to identify any reported 
involvement of parents or patients in outcome selection for the 
included trials. These problems limit the degree to which results 
of neonatal clinical trials are able to advance neonatal care.
The strengths of our review are identification of outcomes 
from a range of international randomised trials, relating to 
babies of all gestational ages, testing a wide range of interven-
tions. We followed a preregistered protocol36 using methods 
developed in previous similar work25–28 and report this review 
in line with PRISMA guidelines.37 Quality of the included trials 
was generally good; 95% of trials scored 3 or more on the Jadad 
scale.44 The main limitation of this systematic review is that it is 
limited to larger neonatal trials (with over 100 infants in each 
arm). Although a more complete view of the outcomes reported 
would be obtained by including all trials, the high number of 
trials identified by our search strategy meant this was unfeasible. 
Furthermore, our results clearly demonstrate inconsistency and 
incompleteness of neonatal outcome reporting which would 
likely be exacerbated by the inclusion of smaller studies. Our 
review was limited to research conducted in a high- income 
setting because there are significant differences in practice 
between high- and low- income settings with distinct fields of 
research.47 Another limitation is that we only included English 
publications and were only able to assess whether there was 
reported involvement of patients and parents in outcome selec-
tion and did not contact trialists directly. Some trials may have 
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Table 1 Comparability of outcome measures and time points for prespecified neonatal outcomes
Outcome
no of studies 
reporting 
outcome,  n=76
Most frequently reported 
outcome measure
no of studies 
reporting outcome 
measure,  n=76
Most frequently reported 
measurement time point
no of studies reporting 
comparable outcome 
measure and time point,  
n=76
Breast feeding 6 (8) Breast feeding (not further 
specified)
3 (4) 3 or 6 or 9 or 12 months of age 2 (3)
Bronchopulmonary dysplasia 49 (64) Need for oxygen at 36 weeks 18 (24) 36 weeks postmenstrual age 18 (24)
Enteral feeding 16 (21) Days to full enteral feeding 
(not further specified)
10 (13) Measurement time point not specified for any study*
Intracranial haemorrhage 36 (47) Papile grade≥3 28 (37) Discharge home 5 (7)
Necrotising enterocolitis 53 (70) Bell’s stage≥2 18 (24) 6 months of age 4 (5)
Parenteral nutrition (PN) use 9 (12) Duration of PN 8 (11) Measurement time point not specified for any study*
Patent ductus arteriosus (PDA) 35 (46) PDA needing surgical ligation 18 (24) Discharge home 4 (5)
Periventricular 
leucomalacia (PVL)
21 (28) Cystic PVL 11 (14) 6 months of age 1 (1)
Respiratory distress 
syndrome (RDS)
7 (9) RDS (not further specified) 7 (9) 10 weeks after start of study 




42 (55) ROP stage≥3 10 (13) Hospital discharge 2 (3)
Sepsis 47 (62) Late onset sepsis 6 (8) Discharge home 2 (3)
Survival 67 (88) Survival 67 (88) Discharge home 37 (49)
Percentage of studies reporting each outcome/measure/time point is given in italics. 
*For some outcomes, the reporting time point was not defined for any study.
which was not reported, but as we found no evidence in any of 
the included trials it seems unlikely such involvement is common 
or would materially alter these stark findings.
Incomplete reporting of important outcomes has been shown 
in many fields48 49 and across women’s and newborn health 
research25 26 50 51; our review demonstrates even an outcome 
as crucial as survival is not universally reported. Common, 
important neonatal morbidities like sepsis and necrotising 
enterocolitis are reported in around two- thirds of papers even 
though these morbidities are known to be multifactorial52 53 
and may be affected by treatments targeted at other systems. 
When these outcomes are reported, the range of different time 
points (23 different time points across 67 trials for survival) and 
outcome measures (43 different measures across 47 trials for 
sepsis) makes comparison between studies impossible. Hetero-
geneity of outcome selection is further illustrated by the large 
number of outcome measures only reported in a single trial 
(639/889), which mirrors the findings of a review of trials in 
oncology.54
Composite outcomes have been challenged because they may 
be considered clinically meaningless,19 can either inflate effect 
sizes55 56 or mask potentially important effects seen in one 
component57 58 and have been explicitly criticised by parents.19 
This review identifies a further limitation of composite outcomes 
in neonatal trials, inconsistency in composite construction and 
reporting: the majority (58/69) of composite outcome measures 
we identified in this review were only used in a single trial. 
Even when researchers measured similar concepts (eg, death 
or disability), a new, incomparable measure was often used 
by individual studies rendering effective meta- analysis of such 
combined end points impossible.
The high degree of inconsistent outcome selection, measure-
ment and reporting we find has important consequences for 
evidence- based neonatology, systematic reviews and meta- 
analyses: the multitude of incomparable outcome measures 
and time points means that only a small portion of the avail-
able evidence can be combined. This is likely to be a key factor 
behind the increasing number of inconclusive Cochrane reviews 
in neonatology.16 Meta- analyses are essential to identify effec-
tive neonatal interventions; they have been instrumental in 
quantifying the beneficial effect of antenatal steroids59 and, 
more recently, delayed cord clamping in preterm neonates.60 
However, the scale of the problem identified here suggests that 
meta- analyses are increasingly unlikely to play such a role in the 
future unless outcome selection and reporting can be improved.
Public and patient involvement is increasingly recognised 
to increase the relevance of research to clinical practice and 
patients’ lives.17 34 Another criticism of clinical trials is that 
outcome selection reflects the needs of researchers rather than 
patients or parents,19 32 and our review supports this critique: we 
found no evidence of patient or parent involvement in outcome 
selection. Beyond survival, we found that the most commonly 
reported outcomes all relate to diagnoses made during the 
neonatal unit admission; this contrasts with the growing body 
of evidence that prematurity or sickness in the neonatal period 
can have effects that last throughout life.4 61 62 The correlation 
between short- term outcomes and longer term difficulties is 
often inaccurate and imprecise19 63 64 and so long- term follow- up 
is important if trials are to provide evidence on how to opti-
mise outcomes throughout childhood and into adult life. In 
other fields, patient input has identified important outcomes not 
previously recognised by researchers.65 66 This review suggests 
that more input from patients and parents is needed, particularly 
in outcome selection as it is known that parents and researchers 
focus on different neonatal outcomes.67
A solution to the problems highlighted in this review, inconsis-
tent outcome reporting and a lack of patient and parent involve-
ment in outcome selection, is the development and application 
of a core outcome set for neonatal medicine. A core outcome 
set is a minimum set of outcomes that can be measured in a 
standardised manner and reported consistently by all trials in a 
field.38 A core outcome set is not intended to limit the outcomes 
recorded by researchers, but rather to specify a minimum set 
of outcomes, standardised outcome measures and standardised 
assessment time points. Core outcome sets have been developed 
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women’s health,69 70 and are underpinned by a robust method-
ology.38 The Core Outcomes in Neonatology project is devel-
oping a core outcome set for neonatal medicine.43
COnClusIOns
There is inconsistency in outcome selection and reporting in 
clinical trials involving neonates: most trials are missing infor-
mation on clinically important outcomes. There is no evidence 
of parent or patient involvement in outcome selection. Devel-
oping and implementing a minimum core outcome set for future 
neonatal trials with input from former patients and parents will 
address these issues.
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